Acute Tubular Necrosis Secondary to Tyrosine Kinase Inhibitor, Dasatinib, in Philadelphia Chromosome Positive ALL and a Review of the Literature

The presence of the Philadelphia chromosome in adult pre-B cell ALL (Ph+ ALL) confers a poor prognosis. Dasatinib is a second generation tyrosine kinase inhibitor (TKI) that targets the BCR-ABL1 fusion protein. It has been studied and approved in chronic phase chronic myeloid leukemia (CML) and Ph+ ALL. The medication ’s renal safety profile has been established in prospective clinical trials, as well as one large retrospective single-institution study.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research